Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831350 · ClinicalTrials.gov registry record · Phase 2
Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
A Phase 2 study, sponsored by Barnes Retina Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00831350 is a Phase 2 study that has completed, run by Barnes Retina Institute. The registered enrollment target is 32 participants.
The verdict
NCT00831350, a Phase 2 study, has completed, sponsored by Barnes Retina Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a study of subjects with retinal vein occlusion (RVO) specifically looking at the difference in outcomes between patients with posterior vitreous detachment (PVD) and those without PVD. Posterior vitreous detachment is a condition where the gel-like substance that occupies the space between the retina and the lens of the eye liquefies and separates from the retina. 20 subjects from Barnes Retina Institute will be enrolled in this study. Based on a pre-treatment ultrasound (a test utilizing high-frequency sound waves to look at the inside of the eye), high resolution OCT (a noninvasive procedure called optical coherence tomography to check the thickness of your retina) and clinical exam, subjects will be assigned to one of 2 groups at baseline: Group 1 will be those with PVD and Group 2 will be those without PVD. Then subjects will receive monthly intravitreal (inside the eye) injections of Ranibizumab.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831350
The ClinicalTrials.gov registry entry for NCT00831350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barnes Retina Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00831350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831350 about?
NCT00831350 is a clinical study titled "Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations". This is a study of subjects with retinal vein occlusion (RVO) specifically looking at the difference in outcomes between patients with posterior vitreous detachment (PVD) and those without PVD. Posterior vitreous detachment is a condition where the gel-like substance that occupies the space between ...
What is the current status of trial NCT00831350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00831350?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00831350?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.